Aditxt, Inc. (ADTX)
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Aditxt, Inc.
- Not computed: short interest % needs a single float figure, and the float on record is a bound or estimate.
- 896.8K
- 1.00
The cost to borrow ADTX shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 1.0%
- 1
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 896.8K sh |
| Oct 15, 2026 | 897.3K sh |
| Sep 30, 2026 | 898.2K sh |
| Sep 15, 2026 | 897.8K sh |
| Aug 31, 2026 | 896.5K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 22, 2026 | 1 sh |
| Oct 13, 2026 | 38.6K sh |
| Sep 2, 2026 | 2 sh |
| Aug 28, 2026 | 431 sh |
| Aug 25, 2026 | 25.2K sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 16, 2026 | 1.0% |
| Nov 13, 2026 | 72.6% |
| Nov 12, 2026 | 2.9% |
| Nov 11, 2026 | 0.1% |
| Nov 10, 2026 | 0.2% |
130 calendar days requested; 91 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for ADTX: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 896,756 ADTX shares were sold short (1.00 days to cover).